{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T11:29:42Z","timestamp":1792150182736,"version":"4.4.0"},"reference-count":94,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001745","name":"Asia Pacific League of Associations for Rheumatology","doi-asserted-by":"publisher","award":["Fellowship Grant 2024"],"award-info":[{"award-number":["Fellowship Grant 2024"]}],"id":[{"id":"10.13039\/501100001745","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Paediatric Rheumatology European Association","award":["Fellowship Grant 2024"],"award-info":[{"award-number":["Fellowship Grant 2024"]}]},{"name":"Versus Arthritis Studentship"},{"name":"NIHR Biomedical Research Centre at GOSH"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"DOI":"10.1186\/s12969-025-01146-8","type":"journal-article","created":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T08:29:42Z","timestamp":1763022582000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Juvenile dermatomyositis: new insights into pathogenesis and clinical applications"],"prefix":"10.1186","volume":"23","author":[{"given":"Pauline PL","family":"Chan Ng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aris E.","family":"Syntakas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy R.","family":"Wedderburn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,13]]},"reference":[{"key":"1146_CR1","doi-asserted-by":"publisher","first-page":"4154","DOI":"10.4049\/jimmunol.168.8.4154","volume":"168","author":"Z Tezak","year":"2002","unstructured":"Tezak Z, Hoffman EP, Lutz JL, et al. Gene expression profiling in DQA1*0501\u2009+\u2009children with untreated dermatomyositis: a novel model of pathogenesis. J Immunol. 2002;168:4154\u201363. https:\/\/doi.org\/10.4049\/jimmunol.168.8.4154.","journal-title":"J Immunol"},{"key":"1146_CR2","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2119\/2006-00085.Baechler","volume":"13","author":"EC Baechler","year":"2007","unstructured":"Baechler EC, Bauer JW, Slattery CA, et al. An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity. Mol Med. 2007;13:59\u201368. https:\/\/doi.org\/10.2119\/2006-00085.Baechler.","journal-title":"Mol Med"},{"key":"1146_CR3","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/ana.20464","volume":"57","author":"SA Greenberg","year":"2005","unstructured":"Greenberg SA, Pinkus JL, Pinkus GS, et al. Interferon-alpha\/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol. 2005;57:664\u201378. https:\/\/doi.org\/10.1002\/ana.20464.","journal-title":"Ann Neurol"},{"key":"1146_CR4","first-page":"605","volume":"31","author":"CK Li","year":"2004","unstructured":"Li CK, Varsani H, Holton JL, et al. MHC class I overexpression on muscles in early juvenile dermatomyositis. J Rheumatol. 2004;31:605\u20139.","journal-title":"J Rheumatol"},{"key":"1146_CR5","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1093\/brain\/awy105","volume":"141","author":"L Ladislau","year":"2018","unstructured":"Ladislau L, Su\u00e1rez-Calvet X, Toquet S, et al. JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis. Brain. 2018;141:1609\u201321. https:\/\/doi.org\/10.1093\/brain\/awy105.","journal-title":"Brain"},{"key":"1146_CR6","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1093\/rheumatology\/kead186","volume":"63","author":"LT Covert","year":"2024","unstructured":"Covert LT, Patel H, Osman A, et al. Effect of type I interferon on engineered pediatric skeletal muscle: a promising model for juvenile dermatomyositis. Rheumatology (Oxford). 2024;63:209\u201317. https:\/\/doi.org\/10.1093\/rheumatology\/kead186.","journal-title":"Rheumatology (Oxford)"},{"key":"1146_CR7","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1002\/art.41639","volume":"73","author":"C Papadopoulou","year":"2021","unstructured":"Papadopoulou C, Hong Y, Krol P, et al. The vasculopathy of juvenile dermatomyositis: endothelial injury, hypercoagulability, and increased arterial stiffness. Arthritis Rheumatol. 2021;73:1253\u201366. https:\/\/doi.org\/10.1002\/art.41639.","journal-title":"Arthritis Rheumatol"},{"key":"1146_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2024.103232","volume":"146","author":"B Huang","year":"2024","unstructured":"Huang B, Li H, Jiang Q, et al. Elevated type I IFN signalling directly affects CD8(+) T-cell distribution and autoantigen recognition of the skeletal muscles in active JDM patients. J Autoimmun. 2024;146:103232. https:\/\/doi.org\/10.1016\/j.jaut.2024.103232.","journal-title":"J Autoimmun"},{"key":"1146_CR9","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.3899\/jrheum.2022-0827","volume":"50","author":"AC Londe","year":"2023","unstructured":"Londe AC, Fernandez-Ruiz R, Julio PR, et al. Type i interferons in autoimmunity: implications in clinical phenotypes and treatment response. J Rheumatol. 2023;50:1103\u201313. https:\/\/doi.org\/10.3899\/jrheum.2022-0827.","journal-title":"J Rheumatol"},{"key":"1146_CR10","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.jpeds.2005.10.032","volume":"148","author":"LM Pachman","year":"2006","unstructured":"Pachman LM, Abbott K, Sinacore JM, et al. Duration of illness is an important variable for untreated children with juvenile dermatomyositis. J Pediatr. 2006;148:247\u201353. https:\/\/doi.org\/10.1016\/j.jpeds.2005.10.032.","journal-title":"J Pediatr"},{"key":"1146_CR11","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1093\/rheumatology\/keab601","volume":"61","author":"B Lerkvaleekul","year":"2022","unstructured":"Lerkvaleekul B, Veldkamp SR, van der Wal MM, et al. Siglec-1 expression on monocytes is associated with the interferon signature in juvenile dermatomyositis and can predict treatment response. Rheumatology (Oxford). 2022;61:2144\u201355. https:\/\/doi.org\/10.1093\/rheumatology\/keab601.","journal-title":"Rheumatology (Oxford)"},{"key":"1146_CR12","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1002\/acr2.11618","volume":"5","author":"C Weiden","year":"2023","unstructured":"Weiden C, Saers M, Schwarz T, et al. Type 1 Interferon-Stimulated gene expression and disease activity in pediatric rheumatic diseases: no composite scores needed?? ACR Open Rheumatol. 2023;5:652\u201362. https:\/\/doi.org\/10.1002\/acr2.11618.","journal-title":"ACR Open Rheumatol"},{"key":"1146_CR13","doi-asserted-by":"publisher","first-page":"604","DOI":"10.3899\/jrheum.2024-0806","volume":"52","author":"JM MacMahon","year":"2025","unstructured":"MacMahon JM, Massumi M, Duong TT, et al. Correlation between interferon response gene score and disease activity in juvenile dermatomyositis. J Rheumatol. 2025;52:604\u201361220250601. https:\/\/doi.org\/10.3899\/jrheum.2024-0806.","journal-title":"J Rheumatol"},{"issue":"20190312","key":"1146_CR14","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1002\/art.40881","volume":"71","author":"J Wienke","year":"2019","unstructured":"Wienke J, Bellutti Enders F, Lim J, et al. Galectin-9 and CXCL10 as biomarkers for disease activity in juvenile dermatomyositis: A longitudinal cohort study and multicohort validation. Arthritis Rheumatol. 2019;71(20190312):1377\u201390. https:\/\/doi.org\/10.1002\/art.40881.","journal-title":"Arthritis Rheumatol"},{"key":"1146_CR15","doi-asserted-by":"publisher","unstructured":"Graf M, von Stuckrad SL, Uruha A, et al. SIGLEC1 enables straightforward assessment of type I interferon activity in idiopathic inflammatory myopathies. RMD Open. 2022;8. https:\/\/doi.org\/10.1136\/rmdopen-2021-001934.","DOI":"10.1136\/rmdopen-2021-001934"},{"issue":"9","key":"1146_CR16","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaf227","volume":"64","author":"SR Veldkamp","year":"2025","unstructured":"Veldkamp SR, Reugebrink M, Evers SW, et al. Targeting interferon responses in juvenile dermatomyositis: Siglec-1 as an in vitro biomarker for JAK inhibitor efficacy. Rheumatology (Oxford). 2025;20250515. https:\/\/doi.org\/10.1093\/rheumatology\/keaf227.","journal-title":"Rheumatology (Oxford)"},{"key":"1146_CR17","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nature04734","volume":"441","author":"H Kato","year":"2006","unstructured":"Kato H, Takeuchi O, Sato S, et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature. 2006;441:101\u20135. https:\/\/doi.org\/10.1038\/nature04734.","journal-title":"Nature"},{"key":"1146_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2024.103686","volume":"23","author":"C Castellini","year":"2024","unstructured":"Castellini C, Scotti C, Navarini L, et al. The evaluation of type I interferon score in dermatomyositis, a systematic review and a meta-analysis. Autoimmun Rev. 2024;23:103686. https:\/\/doi.org\/10.1016\/j.autrev.2024.103686.","journal-title":"Autoimmun Rev"},{"key":"1146_CR19","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1093\/rheumatology\/kez525","volume":"59","author":"I Melki","year":"2020","unstructured":"Melki I, Devilliers H, Gitiaux C, et al. Anti-MDA5 juvenile idiopathic inflammatory myopathy: a specific subgroup defined by differentially enhanced interferon-\u03b1 signalling. Rheumatology (Oxford). 2020;59:1927\u201337. https:\/\/doi.org\/10.1093\/rheumatology\/kez525.","journal-title":"Rheumatology (Oxford)"},{"key":"1146_CR20","doi-asserted-by":"publisher","first-page":"Si240","DOI":"10.1093\/rheumatology\/keae082","volume":"63","author":"LT Covert","year":"2024","unstructured":"Covert LT, Prinz JA, Swain-Lenz D, et al. Genetic changes from type I interferons and JAK inhibitors: clues to drivers of juvenile dermatomyositis. Rheumatology (Oxford). 2024;63:Si240\u20138. https:\/\/doi.org\/10.1093\/rheumatology\/keae082.","journal-title":"Rheumatology (Oxford)"},{"key":"1146_CR21","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1111\/bjd.15006","volume":"176","author":"C Huard","year":"2017","unstructured":"Huard C, Gull\u00e0 SV, Bennett DV, et al. Correlation of cutaneous disease activity with type 1 interferon gene signature and interferon \u03b2 in dermatomyositis. Br J Dermatol. 2017;176:1224\u201330. https:\/\/doi.org\/10.1111\/bjd.15006.","journal-title":"Br J Dermatol"},{"key":"1146_CR22","doi-asserted-by":"publisher","first-page":"25537","DOI":"10.1038\/s41598-025-10895-1","volume":"15","author":"A Yoshida","year":"2025","unstructured":"Yoshida A, Gono T, Okazaki Y, et al. Dysregulated type I\/III interferon system in circulation from patients with anti-MDA5-positive dermatomyositis. Sci Rep. 2025;15:25537. https:\/\/doi.org\/10.1038\/s41598-025-10895-1.","journal-title":"Sci Rep"},{"key":"1146_CR23","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.1093\/rheumatology\/keac627","volume":"62","author":"M Kogami","year":"2023","unstructured":"Kogami M, Abe Y, Ando T, et al. Changes in anti-MDA5 antibody titres and serum cytokine levels before and after diagnosis of anti-MDA5 antibody-positive dermatomyositis. Rheumatology (Oxford). 2023;62:2525\u201333. https:\/\/doi.org\/10.1093\/rheumatology\/keac627.","journal-title":"Rheumatology (Oxford)"},{"key":"1146_CR24","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1186\/s13075-018-1737-2","volume":"20","author":"Y Ishikawa","year":"2018","unstructured":"Ishikawa Y, Iwata S, Hanami K, et al. Relevance of interferon-gamma in pathogenesis of life-threatening rapidly progressive interstitial lung disease in patients with dermatomyositis. Arthritis Res Ther. 2018;20:240. https:\/\/doi.org\/10.1186\/s13075-018-1737-2.","journal-title":"Arthritis Res Ther"},{"key":"1146_CR25","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1136\/adc.69.2.232","volume":"69","author":"F De Benedetti","year":"1993","unstructured":"De Benedetti F, De Amici M, Aramini L, et al. Correlation of serum neopterin concentrations with disease activity in juvenile dermatomyositis. Arch Dis Child. 1993;69:232\u20135. https:\/\/doi.org\/10.1136\/adc.69.2.232.","journal-title":"Arch Dis Child"},{"key":"1146_CR26","first-page":"1681","volume":"48","author":"LG Rider","year":"2002","unstructured":"Rider LG, Schiffenbauer AS, Zito M, et al. Neopterin and quinolinic acid are surrogate measures of disease activity in the juvenile idiopathic inflammatory myopathies. Clin Chem. 2002;48:1681\u20138.","journal-title":"Clin Chem"},{"issue":"1","key":"1146_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12010008","volume":"12","author":"A Khojah","year":"2021","unstructured":"Khojah A, Morgan G, Pachman LM. Clues to disease activity in juvenile dermatomyositis: neopterin and other biomarkers. Diagnostics. 2021;12(1):12(20211221). https:\/\/doi.org\/10.3390\/diagnostics12010008.","journal-title":"Diagnostics"},{"key":"1146_CR28","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1111\/cei.13404","volume":"199","author":"QL Peng","year":"2020","unstructured":"Peng QL, Zhang YM, Liang L, et al. A high level of serum neopterin is associated with rapidly progressive interstitial lung disease and reduced survival in dermatomyositis. Clin Exp Immunol. 2020;199:314\u201325. https:\/\/doi.org\/10.1111\/cei.13404.","journal-title":"Clin Exp Immunol"},{"key":"1146_CR29","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1080\/14397595.2018.1548918","volume":"29","author":"A Nishioka","year":"2019","unstructured":"Nishioka A, Tsunoda S, Abe T, et al. Serum neopterin as well as ferritin, soluble interleukin-2 receptor, KL-6 and anti-MDA5 antibody titer provide markers of the response to therapy in patients with interstitial lung disease complicating anti-MDA5 antibody-positive dermatomyositis. Mod Rheumatol. 2019;29:814\u201320. https:\/\/doi.org\/10.1080\/14397595.2018.1548918.","journal-title":"Mod Rheumatol"},{"issue":"20240208","key":"1146_CR30","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1080\/1744666x.2024.2312819","volume":"20","author":"H Kim","year":"2024","unstructured":"Kim H. Updates on efficacy and safety Janus kinase inhibitors in juvenile dermatomyositis. Expert Rev Clin Immunol. 2024;20(20240208):589\u2013602. https:\/\/doi.org\/10.1080\/1744666x.2024.2312819.","journal-title":"Expert Rev Clin Immunol"},{"key":"1146_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2024.152426","volume":"66","author":"S Sener","year":"2024","unstructured":"Sener S, Cam V, Ozen S, et al. Treatment with Janus kinase inhibitors in juvenile dermatomyositis: a review of the literature. Semin Arthritis Rheum. 2024;66:152426. https:\/\/doi.org\/10.1016\/j.semarthrit.2024.152426.","journal-title":"Semin Arthritis Rheum"},{"issue":"9","key":"1146_CR32","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaf225","volume":"64","author":"Z Wang","year":"2025","unstructured":"Wang Z, Lu Y, Qiu X, et al. Long-term effectiveness and safety of baricitinib treatment on refractory or severe juvenile dermatomyositis. Rheumatology (Oxford). 2025;20250502. https:\/\/doi.org\/10.1093\/rheumatology\/keaf225.","journal-title":"Rheumatology (Oxford)"},{"key":"1146_CR33","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s12969-021-00637-8","volume":"19","author":"MG Ll Wilkinson","year":"2021","unstructured":"Ll Wilkinson MG, Deakin CT, Papadopoulou C, et al. JAK inhibitors: a potential treatment for JDM in the context of the role of interferon-driven pathology. Pediatr Rheumatol Online J. 2021;19:146. https:\/\/doi.org\/10.1186\/s12969-021-00637-8.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"9","key":"1146_CR34","first-page":"76","volume":"76","author":"KA Chinoy h","year":"2025","unstructured":"Chinoy h KA, Sylvestre Y, Lilleker J, Gordon P, Tansley S, Prabu A, Aslam A, Snedden A, Lamb J, Accessed. aricitinib in the Treatment of Adult Idiopathic Inflammatory Myopathy: A Randomized, Treatment Delayed-Start Clinical Trial [abstract]. Arthritis Rheumatol. 2025;76(9):76.","journal-title":"Arthritis Rheumatol"},{"key":"1146_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s12969-024-01044-5","volume":"23","author":"V Natoli","year":"2025","unstructured":"Natoli V, Palmeri S, Rebollo-Gim\u00e9nez AI, et al. Successful treatment of an anti-MDA5 antibody-positive juvenile dermatomyositis patient with refractory interstitial lung disease using tofacitinib. Pediatr Rheumatol Online J. 2025;23:22. https:\/\/doi.org\/10.1186\/s12969-024-01044-5.","journal-title":"Pediatr Rheumatol Online J"},{"key":"1146_CR36","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1111\/1756-185x.14258","volume":"25","author":"PLP Chan Ng","year":"2022","unstructured":"Chan Ng PLP, Mopur A, Goh DYT, et al. Janus kinase inhibition in induction treatment of anti-MDA5 juvenile dermatomyositis-associated rapidly progressive interstitial lung disease. Int J Rheum Dis. 2022;25:228\u201331. https:\/\/doi.org\/10.1111\/1756-185x.14258.","journal-title":"Int J Rheum Dis"},{"key":"1146_CR37","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1080\/25785826.2024.2336687","volume":"47","author":"S Yamazaki","year":"2024","unstructured":"Yamazaki S, Shimizu M, Yakabe A, et al. Successful treatment with Tofacitinib for anti-melanoma differentiation-associated gene 5 antibody-positive juvenile dermatomyositis: case reports and review of the literature. Immunol Med. 2024;47:110\u20137. https:\/\/doi.org\/10.1080\/25785826.2024.2336687.","journal-title":"Immunol Med"},{"key":"1146_CR38","unstructured":"Baricitinib in the treatment of new-onset juvenile dermatomyositis (MYOCIT). USA clinical trials registry 2022. US Clinical Trials Registry Clinical Trial NCT05524311. https:\/\/doi.org\/ichgcp.net\/clinical-trials-registry\/NCT05524311"},{"key":"1146_CR39","doi-asserted-by":"publisher","unstructured":"Papadopoulou C, et al. Elicitation of expert prior opinion to design the BARJDM trial in juvenile dermatomyositis. Rheumatology (Oxford). 2024;63(12):3271\u201378.\u00a0https:\/\/doi.org\/10.1093\/rheumatology\/keae392.","DOI":"10.1093\/rheumatology\/keae392"},{"key":"1146_CR40","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jdcr.2023.10.023","volume":"43","author":"PS Ang","year":"2024","unstructured":"Ang PS, Ezenwa E, Ko K, et al. Refractory dermatomyositis responsive to anifrolumab. JAAD Case Rep. 2024;43:27\u20139. https:\/\/doi.org\/10.1016\/j.jdcr.2023.10.023.","journal-title":"JAAD Case Rep"},{"issue":"2","key":"1146_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2025.04.025","volume":"93","author":"A Srivatsa","year":"2025","unstructured":"Srivatsa A, Rehman W, Rehman R, et al. A novel treatment for refractory dermatomyositis: a systematic review of anifrolumab and dermatomyositis. J Am Acad Dermatol. 2025;20250412. https:\/\/doi.org\/10.1016\/j.jaad.2025.04.025.","journal-title":"J Am Acad Dermatol"},{"key":"1146_CR42","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1016\/j.ard.2025.02.002","volume":"84","author":"C Triaille","year":"2025","unstructured":"Triaille C, Piram M, Ellezam B, et al. Rapid clinical and transcriptomic response to anifrolumab in refractory anti-TIF1\u03b3-positive juvenile dermatomyositis. Ann Rheum Dis. 2025;84:1052\u2013105420250411. https:\/\/doi.org\/10.1016\/j.ard.2025.02.002.","journal-title":"Ann Rheum Dis"},{"key":"1146_CR43","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1001\/jamadermatol.2023.4744","volume":"160","author":"KS Shaw","year":"2024","unstructured":"Shaw KS, Reusch DB, Castillo RL, et al. Rapid improvement in recalcitrant cutaneous juvenile dermatomyositis with anifrolumab treatment. JAMA Dermatol. 2024;160:237\u20138. https:\/\/doi.org\/10.1001\/jamadermatol.2023.4744.","journal-title":"JAMA Dermatol"},{"key":"1146_CR44","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1093\/bjd\/ljaf064","volume":"192","author":"LH Shayegan","year":"2025","unstructured":"Shayegan LH, Shaw KS, Wieschhoff GG, et al. Improvement in dermatomyositis-associated muscle disease with anifrolumab. Br J Dermatol. 2025;192:1126\u20138. https:\/\/doi.org\/10.1093\/bjd\/ljaf064.","journal-title":"Br J Dermatol"},{"key":"1146_CR45","doi-asserted-by":"publisher","unstructured":"Guirguis J, Ramachandran V, Ann Vleugels R, et al. Monoclonal antibody targeting IFN\u03b2 for the treatment of NXP2-positive ulcerative juvenile dermatomyositis. Pediatrics. 2025;155. https:\/\/doi.org\/10.1542\/peds.2024-067481.","DOI":"10.1542\/peds.2024-067481"},{"key":"1146_CR46","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/s0140-6736(24)02071-3","volume":"405","author":"D Fiorentino","year":"2025","unstructured":"Fiorentino D, Mangold AR, Werth VP, et al. Efficacy, safety, and target engagement of dazukibart, an IFN\u03b2 specific monoclonal antibody, in adults with dermatomyositis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2025;405:137\u201346. https:\/\/doi.org\/10.1016\/s0140-6736(24)02071-3.","journal-title":"Lancet"},{"key":"1146_CR47","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3389\/fped.2018.00284","volume":"6","author":"C Papadopoulou","year":"2018","unstructured":"Papadopoulou C, McCann LJ. The vasculopathy of juvenile dermatomyositis. Front Pediatr. 2018;6:284. https:\/\/doi.org\/10.3389\/fped.2018.00284.","journal-title":"Front Pediatr"},{"key":"1146_CR48","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.3899\/jrheum.181275","volume":"47","author":"T Kishi","year":"2020","unstructured":"Kishi T, Chipman J, Evereklian M, et al. Endothelial activation markers as disease activity and damage measures in juvenile dermatomyositis. J Rheumatol. 2020;47:1011\u20138. https:\/\/doi.org\/10.3899\/jrheum.181275.","journal-title":"J Rheumatol"},{"key":"1146_CR49","first-page":"801","volume":"31","author":"AM Sallum","year":"2004","unstructured":"Sallum AM, Marie SK, Wakamatsu A, et al. Immunohistochemical analysis of adhesion molecule expression on muscle biopsy specimens from patients with juvenile dermatomyositis. J Rheumatol. 2004;31:801\u20137.","journal-title":"J Rheumatol"},{"key":"1146_CR50","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13075-025-03520-z","volume":"27","author":"SS Bae","year":"2025","unstructured":"Bae SS, Shahbazian A, Wang J, et al. Plasma levels of adhesion molecules are elevated in dermatomyositis-interstitial lung disease and associated with low paraoxonase-1 activity. Arthritis Res Ther. 2025;27:53. https:\/\/doi.org\/10.1186\/s13075-025-03520-z.","journal-title":"Arthritis Res Ther"},{"issue":"20210224","key":"1146_CR51","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1080\/03009742.2020.1861647","volume":"50","author":"A Notarnicola","year":"2021","unstructured":"Notarnicola A, Barsotti S, N\u00e4sman L, et al. Evaluation of risk factors and biomarkers related to arterial and venous thrombotic events in idiopathic inflammatory myopathies. Scand J Rheumatol. 2021;50(20210224):390\u20137. https:\/\/doi.org\/10.1080\/03009742.2020.1861647.","journal-title":"Scand J Rheumatol"},{"key":"1146_CR52","first-page":"1623","volume":"33","author":"D Figarella-Branger","year":"2006","unstructured":"Figarella-Branger D, Schleinitz N, Bouti\u00e8re-Alban\u00e8se B, et al. Platelet-endothelial cell adhesion molecule-1 and CD146: soluble levels and in situ expression of cellular adhesion molecules implicated in the cohesion of endothelial cells in idiopathic inflammatory myopathies. J Rheumatol. 2006;33:1623\u201330.","journal-title":"J Rheumatol"},{"issue":"20130124","key":"1146_CR53","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/1756-185x.12039","volume":"16","author":"VS Limaye","year":"2013","unstructured":"Limaye VS, Bonder CS, Sun WY, et al. Levels of soluble adhesion molecules and their associations in inflammatory myositis. Int J Rheum Dis. 2013;16(20130124):99\u2013101. https:\/\/doi.org\/10.1111\/1756-185x.12039.","journal-title":"Int J Rheum Dis"},{"key":"1146_CR54","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1046\/j.1365-2133.2000.03668.x","volume":"143","author":"M Kubo","year":"2000","unstructured":"Kubo M, Ihn H, Yamane K, et al. Increased serum levels of soluble vascular cell adhesion molecule-1 and soluble E-selectin in patients with polymyositis\/dermatomyositis. Br J Dermatol. 2000;143:392\u20138. https:\/\/doi.org\/10.1046\/j.1365-2133.2000.03668.x.","journal-title":"Br J Dermatol"},{"key":"1146_CR55","doi-asserted-by":"publisher","unstructured":"Gibbs E, Khojah A, Morgan G, et al. The von Willebrand factor antigen reflects the juvenile dermatomyositis disease activity score. Biomedicines. 2023;11(20230214). https:\/\/doi.org\/10.3390\/biomedicines11020552.","DOI":"10.3390\/biomedicines11020552"},{"key":"1146_CR56","doi-asserted-by":"publisher","first-page":"e8611","DOI":"10.7717\/peerj.8611","volume":"8","author":"D Zhong","year":"2020","unstructured":"Zhong D, Wu C, Bai J, et al. Co-expression network analysis reveals the pivotal role of mitochondrial dysfunction and interferon signature in juvenile dermatomyositis. PeerJ. 2020;8:e8611. https:\/\/doi.org\/10.7717\/peerj.8611.","journal-title":"PeerJ"},{"key":"1146_CR57","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1136\/ard-2022-223469","volume":"82","author":"MGL Wilkinson","year":"2023","unstructured":"Wilkinson MGL, Moulding D, McDonnell TCR, et al. Role of CD14\u2009+\u2009monocyte-derived oxidised mitochondrial DNA in the inflammatory interferon type 1 signature in juvenile dermatomyositis. Ann Rheum Dis. 2023;82:658\u201369. https:\/\/doi.org\/10.1136\/ard-2022-223469.","journal-title":"Ann Rheum Dis"},{"key":"1146_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2023.103061","volume":"138","author":"B Duvvuri","year":"2023","unstructured":"Duvvuri B, Pachman LM, Hermanson P, et al. Role of mitochondria in the myopathy of juvenile dermatomyositis and implications for skeletal muscle calcinosis. J Autoimmun. 2023;138:103061. https:\/\/doi.org\/10.1016\/j.jaut.2023.103061.","journal-title":"J Autoimmun"},{"key":"1146_CR59","doi-asserted-by":"publisher","first-page":"20250313","DOI":"10.1172\/jci.insight.179875","volume":"10","author":"JL Turnier","year":"2025","unstructured":"Turnier JL, Vandenbergen SM, McClune ME, et al. Tape strip expression profiling of juvenile dermatomyositis skin reveals mitochondrial dysfunction contributing to disease endotype. JCI Insight. 2025;10:20250313. https:\/\/doi.org\/10.1172\/jci.insight.179875.","journal-title":"JCI Insight"},{"key":"1146_CR60","doi-asserted-by":"publisher","unstructured":"Syntakas AE, Kartawinata M, Evans NML et al. Spatial transcriptomic analysis of muscle biopsy from patients with treatment-naive juvenile dermatomyositis patients reveals mitochondrial abnormalities despite disease-related interferon driven signature. On line ahead of print. https:\/\/doi.org\/10.1016\/j.ard.2025.07.015.","DOI":"10.1016\/j.ard.2025.07.015"},{"key":"1146_CR61","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s00401-017-1731-9","volume":"134","author":"A Meyer","year":"2017","unstructured":"Meyer A, Laverny G, Allenbach Y, et al. IFN-\u03b2-induced reactive oxygen species and mitochondrial damage contribute to muscle impairment and inflammation maintenance in dermatomyositis. Acta Neuropathol. 2017;134:655\u201366620170616. https:\/\/doi.org\/10.1007\/s00401-017-1731-9.","journal-title":"Acta Neuropathol"},{"key":"1146_CR62","doi-asserted-by":"publisher","first-page":"181","DOI":"10.5606\/ArchRheumatol.2017.6175","volume":"32","author":"Y Yang","year":"2017","unstructured":"Yang Y, Yin G, Hao J, et al. Serum interleukin-18 level is associated with disease activity and interstitial lung disease in patients with dermatomyositis. Arch Rheumatol. 2017;32:181\u20138. https:\/\/doi.org\/10.5606\/ArchRheumatol.2017.6175.","journal-title":"Arch Rheumatol"},{"key":"1146_CR63","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1136\/annrheumdis-2012-eular.1196","volume":"71","author":"S Takezaki","year":"2012","unstructured":"Takezaki S, Yamazaki Y, Okura Y, et al. AB1198 IL-18 is a hallmark of juvenile dermatomyositis-associated interstitial pneumonia. Ann Rheum Dis. 2012;71:706. https:\/\/doi.org\/10.1136\/annrheumdis-2012-eular.1196.","journal-title":"Ann Rheum Dis"},{"key":"1146_CR64","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1093\/rheumatology\/keq196","volume":"49","author":"T Gono","year":"2010","unstructured":"Gono T, Kawaguchi Y, Sugiura T, et al. Interleukin-18 is a key mediator in dermatomyositis: potential contribution to development of interstitial lung disease. Rheumatology (Oxford). 2010;49:1878\u201381. https:\/\/doi.org\/10.1093\/rheumatology\/keq196.","journal-title":"Rheumatology (Oxford)"},{"key":"1146_CR65","doi-asserted-by":"publisher","first-page":"841732","DOI":"10.3389\/fimmu.2022.841732","volume":"13","author":"R You","year":"2022","unstructured":"You R, He X, Zeng Z, et al. Pyroptosis and its role in autoimmune disease: a potential therapeutic target. Front Immunol. 2022;13:841732. https:\/\/doi.org\/10.3389\/fimmu.2022.841732.","journal-title":"Front Immunol"},{"key":"1146_CR66","doi-asserted-by":"publisher","first-page":"231","DOI":"10.3389\/fncel.2015.00231","volume":"9","author":"S Van Rossom","year":"2015","unstructured":"Van Rossom S, Op de Beeck K, Hristovska V, et al. The deafness gene DFNA5 induces programmed cell death through mitochondria and MAPK-related pathways. Front Cell Neurosci. 2015;9:231. https:\/\/doi.org\/10.3389\/fncel.2015.00231.","journal-title":"Front Cell Neurosci"},{"key":"1146_CR67","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1093\/rheumatology\/keaa473","volume":"60","author":"D Liu","year":"2021","unstructured":"Liu D, Xiao Y, Zhou B, et al. PKM2-dependent glycolysis promotes skeletal muscle cell pyroptosis by activating the NLRP3 inflammasome in dermatomyositis\/polymyositis. Rheumatology (Oxford). 2021;60:2177\u201389. https:\/\/doi.org\/10.1093\/rheumatology\/keaa473.","journal-title":"Rheumatology (Oxford)"},{"key":"1146_CR68","doi-asserted-by":"publisher","first-page":"61","DOI":"10.2147\/ccid.S492340","volume":"18","author":"W Qiao","year":"2025","unstructured":"Qiao W, Zhu C, Huang D, et al. The role of pyroptosis-related gene signature and immune infiltration in juvenile dermatomyositis. Clin Cosmet Investig Dermatol. 2025;18:61\u201376. https:\/\/doi.org\/10.2147\/ccid.S492340.","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"1146_CR69","doi-asserted-by":"publisher","first-page":"20200213","DOI":"10.1172\/jci.insight.134189","volume":"5","author":"N Seto","year":"2020","unstructured":"Seto N, Torres-Ruiz JJ, Carmona-Rivera C, et al. Neutrophil dysregulation is pathogenic in idiopathic inflammatory myopathies. JCI Insight. 2020;5:20200213. https:\/\/doi.org\/10.1172\/jci.insight.134189.","journal-title":"JCI Insight"},{"key":"1146_CR70","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1002\/art.42615","volume":"75","author":"JM Ward","year":"2023","unstructured":"Ward JM, Ambatipudi M, O\u2019Hanlon TP, et al. Shared and distinctive transcriptomic and proteomic pathways in adult and juvenile dermatomyositis. Arthritis Rheumatol. 2023;75:2014\u201326. https:\/\/doi.org\/10.1002\/art.42615.","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"1146_CR71","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1002\/art.41078","volume":"72","author":"B Duvvuri","year":"2020","unstructured":"Duvvuri B, Pachman LM, Morgan G, et al. Neutrophil extracellular traps in tissue and periphery in juvenile dermatomyositis. Arthritis Rheumatol. 2020;72(2):348\u201358. https:\/\/doi.org\/10.1002\/art.41078.","journal-title":"Arthritis Rheumatol"},{"key":"1146_CR72","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.jaut.2017.06.007","volume":"84","author":"SL Tansley","year":"2017","unstructured":"Tansley SL, Simou S, Shaddick G, et al. Autoantibodies in juvenile-onset myositis: their diagnostic value and associated clinical phenotype in a large UK cohort. J Autoimmun. 2017;84:55\u201364. https:\/\/doi.org\/10.1016\/j.jaut.2017.06.007.","journal-title":"J Autoimmun"},{"key":"1146_CR73","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01372","volume":"9","author":"CJM Piper","year":"2018","unstructured":"Piper CJM, Wilkinson MGL, Deakin CT, et al. CD19(+)CD24(hi)CD38(hi) B cells are expanded in juvenile dermatomyositis and exhibit a pro-inflammatory phenotype after activation through Toll-Like receptor 7 and Interferon-\u03b1. Front Immunol. 2018;9:1372. https:\/\/doi.org\/10.3389\/fimmu.2018.01372.","journal-title":"Front Immunol"},{"key":"1146_CR74","doi-asserted-by":"publisher","first-page":"20230808","DOI":"10.3390\/diagnostics13162626","volume":"13","author":"C Costin","year":"2023","unstructured":"Costin C, Khojah A, Ochfeld E, et al. B cell lymphocytosis in juvenile dermatomyositis. Diagnostics (Basel). 2023;13:20230808. https:\/\/doi.org\/10.3390\/diagnostics13162626.","journal-title":"Diagnostics (Basel)"},{"key":"1146_CR75","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1002\/art.42446","volume":"75","author":"JS Gofshteyn","year":"2023","unstructured":"Gofshteyn JS, Mansfield L, Spitznagle J, et al. Association of juvenile dermatomyositis disease activity with the expansion of blood memory B and T cell subsets lacking follicular markers. Arthritis Rheumatol. 2023;75:1246\u201361. https:\/\/doi.org\/10.1002\/art.42446.","journal-title":"Arthritis Rheumatol"},{"key":"1146_CR76","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.176963","author":"G Rabadam","year":"2024","unstructured":"Rabadam G, Wibrand C, Flynn E, et al. Coordinated immune dysregulation in juvenile dermatomyositis revealed by single-cell genomics. JCI Insight. 2024. https:\/\/doi.org\/10.1172\/jci.insight.176963.","journal-title":"JCI Insight"},{"key":"1146_CR77","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1136\/ard-2024-225773","volume":"83","author":"I Pinal-Fernandez","year":"2024","unstructured":"Pinal-Fernandez I, Munoz-Braceras S, Casal-Dominguez M, et al. Pathological autoantibody internalisation in myositis. Ann Rheum Dis. 2024;83:1549\u201360. https:\/\/doi.org\/10.1136\/ard-2024-225773.","journal-title":"Ann Rheum Dis"},{"key":"1146_CR78","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1136\/ard-2023-223873","volume":"82","author":"I Pinal-Fernandez","year":"2023","unstructured":"Pinal-Fernandez I, Milisenda JC, Pak K, et al. Transcriptional derepression of CHD4\/NuRD-regulated genes in the muscle of patients with dermatomyositis and anti-Mi2 autoantibodies. Ann Rheum Dis. 2023;82:1091\u20137. https:\/\/doi.org\/10.1136\/ard-2023-223873.","journal-title":"Ann Rheum Dis"},{"key":"1146_CR79","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1002\/art.37754","volume":"65","author":"CV Oddis","year":"2013","unstructured":"Oddis CV, Reed AM, Aggarwal R, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum. 2013;65:314\u201324. https:\/\/doi.org\/10.1002\/art.37754.","journal-title":"Arthritis Rheum"},{"key":"1146_CR80","doi-asserted-by":"publisher","first-page":"1301109","DOI":"10.3389\/fimmu.2023.1301109","volume":"14","author":"S Chen","year":"2023","unstructured":"Chen S, Yang J, He D, et al. Anti-SRP immune-mediated necrotizing myopathy responsive to ofatumumab: a case report. Front Immunol. 2023;14:1301109. https:\/\/doi.org\/10.3389\/fimmu.2023.1301109.","journal-title":"Front Immunol"},{"key":"1146_CR81","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.1093\/rheumatology\/kead424","volume":"63","author":"C Wen","year":"2024","unstructured":"Wen C, Yang J, Wei D, et al. Anti-signal recognition particle antibody-positive immune-mediated necrotizing myopathy treated with ofatumumab. Rheumatology (Oxford). 2024;63:e53\u20135. https:\/\/doi.org\/10.1093\/rheumatology\/kead424.","journal-title":"Rheumatology (Oxford)"},{"key":"1146_CR82","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1136\/annrheumdis-2021-221756","volume":"81","author":"P Kvacskay","year":"2022","unstructured":"Kvacskay P, Merkt W, G\u00fcnther J, et al. Obinutuzumab in connective tissue diseases after former rituximab-non-response: a case series. Ann Rheum Dis. 2022;81:744\u20136. https:\/\/doi.org\/10.1136\/annrheumdis-2021-221756.","journal-title":"Ann Rheum Dis"},{"key":"1146_CR83","doi-asserted-by":"publisher","first-page":"460","DOI":"10.55563\/clinexprheumatol\/monpb6","volume":"42","author":"CG Chua","year":"2024","unstructured":"Chua CG, Chai GT, Lim XR, et al. Successful rescue treatment of refractory anti-MDA5 autoantibody positive dermatomyositis with rapidly progressive interstitial lung disease using daratumumab. Clin Exp Rheumatol. 2024;42:460\u20131. https:\/\/doi.org\/10.55563\/clinexprheumatol\/monpb6.","journal-title":"Clin Exp Rheumatol"},{"key":"1146_CR84","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.chest.2022.08.2209","volume":"163","author":"MT Holzer","year":"2023","unstructured":"Holzer MT, Nies JF, Oqueka T, et al. Successful rescue therapy with daratumumab in rapidly progressive interstitial lung disease caused by MDA5-Positive dermatomyositis. Chest. 2023;163:e1\u20135. https:\/\/doi.org\/10.1016\/j.chest.2022.08.2209.","journal-title":"Chest"},{"key":"1146_CR85","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003238","author":"L Ostendorf","year":"2023","unstructured":"Ostendorf L, Muench F, Thorm\u00e4hlen L, et al. Rescue combination treatment of anti-MDA5-associated ARDS with daratumumab. RMD Open. 2023. https:\/\/doi.org\/10.1136\/rmdopen-2023-003238.","journal-title":"RMD Open"},{"key":"1146_CR86","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1136\/ard-2022-223541","volume":"82","author":"O Landon-Cardinal","year":"2023","unstructured":"Landon-Cardinal O, Allard-Chamard H, Chapdelaine H, et al. Daratumumab as a rescue therapy in severe refractory anti-SRP immune-mediated necrotising myopathy. Ann Rheum Dis. 2023;82:579\u201380. https:\/\/doi.org\/10.1136\/ard-2022-223541.","journal-title":"Ann Rheum Dis"},{"issue":"20240501","key":"1146_CR87","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.jaad.2024.04.060","volume":"91","author":"Y Liu","year":"2024","unstructured":"Liu Y, Li Y, Shen T, et al. Belimumab ameliorates symptoms and disease activity in patients with dermatomyositis and juvenile dermatomyositis refractory to standard therapy: a retrospective observational study. J Am Acad Dermatol. 2024;91(20240501):524\u20137. https:\/\/doi.org\/10.1016\/j.jaad.2024.04.060.","journal-title":"J Am Acad Dermatol"},{"key":"1146_CR88","doi-asserted-by":"publisher","first-page":"4006","DOI":"10.1093\/rheumatology\/kead298","volume":"62","author":"S Julien","year":"2023","unstructured":"Julien S, van der Woning B, De Ceuninck L, et al. Efgartigimod restores muscle function in a humanized mouse model of immune-mediated necrotizing myopathy. Rheumatology (Oxford). 2023;62:4006\u201311. https:\/\/doi.org\/10.1093\/rheumatology\/kead298.","journal-title":"Rheumatology (Oxford)"},{"key":"1146_CR89","doi-asserted-by":"publisher","first-page":"1447182","DOI":"10.3389\/fimmu.2024.1447182","volume":"15","author":"M Yang","year":"2024","unstructured":"Yang M, Yuan J, Wang Y, et al. Treatment of refractory immune-mediated necrotizing myopathy with Efgartigimod. Front Immunol. 2024;15:1447182. https:\/\/doi.org\/10.3389\/fimmu.2024.1447182.","journal-title":"Front Immunol"},{"key":"1146_CR90","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","volume":"390","author":"F M\u00fcller","year":"2024","unstructured":"M\u00fcller F, Taubmann J, Bucci L, et al. CD19 CAR t-cell therapy in autoimmune disease - a case series with follow-up. N Engl J Med. 2024;390:687\u2013700. https:\/\/doi.org\/10.1056\/NEJMoa2308917.","journal-title":"N Engl J Med"},{"key":"1146_CR91","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/art.42933","volume":"76","author":"R Nicolai","year":"2024","unstructured":"Nicolai R, Merli P, Moran Alvarez P, et al. Autologous CD19-Targeting CAR T cells in a patient with refractory juvenile dermatomyositis. Arthritis Rheumatol. 2024;76:1560\u20135. https:\/\/doi.org\/10.1002\/art.42933.","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"1146_CR92","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2025.100676","volume":"6","author":"A Par\u00eds-Mu\u00f1oz","year":"2025","unstructured":"Par\u00eds-Mu\u00f1oz A, Alcobendas-Rueda RM, Verd\u00fa-S\u00e1nchez C, et al. CD19 CAR-T cell therapy in a pediatric patient with MDA5(+) dermatomyositis and rapidly progressive interstitial lung disease. Med. 2025;100676. https:\/\/doi.org\/10.1016\/j.medj.2025.100676.","journal-title":"Med"},{"key":"1146_CR93","doi-asserted-by":"publisher","first-page":"e434","DOI":"10.1016\/s2665-9913(24)00377-1","volume":"7","author":"M Scherlinger","year":"2025","unstructured":"Scherlinger M, Nocturne G, Radic M, et al. CAR T-cell therapy in autoimmune diseases: where are we and where are we going? Lancet Rheumatol. 2025;7:e434\u201347. https:\/\/doi.org\/10.1016\/s2665-9913(24)00377-1.","journal-title":"Lancet Rheumatol"},{"key":"1146_CR94","doi-asserted-by":"publisher","first-page":"e424","DOI":"10.1016\/s2665-9913(25)00091-8","volume":"7","author":"M Hagen","year":"2025","unstructured":"Hagen M, M\u00fcller F, Wirsching A, et al. Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with autoimmune disease: an observational study. Lancet Rheumatol. 2025;7:e424\u201333. https:\/\/doi.org\/10.1016\/s2665-9913(25)00091-8.","journal-title":"Lancet Rheumatol"}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-025-01146-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12969-025-01146-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-025-01146-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T08:29:46Z","timestamp":1763022586000},"score":1,"resource":{"primary":{"URL":"https:\/\/ped-rheum.biomedcentral.com\/articles\/10.1186\/s12969-025-01146-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,13]]},"references-count":94,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1146"],"URL":"https:\/\/doi.org\/10.1186\/s12969-025-01146-8","relation":{},"ISSN":["1546-0096"],"issn-type":[{"value":"1546-0096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,13]]},"assertion":[{"value":"29 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Consent for publication"}},{"value":"LRW declares consultancies with Pfizer and Cabaletta paid to UCL unrelated to this review, and research grant from Pfizer paid to UCL, unrelated to this review.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Competing interests"}}],"article-number":"115"}}